MICROPORT-微创医疗(00853)发布2024年度业绩，股东应占亏损2.14亿美元，同比收窄55.2%

Core Viewpoint - MicroPort Medical's 2024 annual performance shows a revenue of $1.031 billion, with a year-on-year growth of 8.5%, and a significant reduction in net loss to$ 214 million, down 55.2% from the previous year [1][2] Group 1: Financial Performance - Revenue for the reporting period reached $1.031 billion, reflecting a 10% year-on-year growth when excluding foreign exchange impacts [1] - The net loss narrowed significantly, attributed to a strong performance in overseas business, which saw an 85% year-on-year increase in revenue [1] - Total expenses for sales, management, and R&D decreased by$ 216.5 million, a 24% reduction year-on-year, with the operating expense ratio dropping by 29 percentage points [1] Group 2: Strategic Initiatives - The company has established a global commercialization platform to facilitate rapid market entry and sales of products developed in China, covering over 20,000 hospitals in more than 100 countries and regions [2] - The company received 58 first-time registration certificates for Class III medical devices from the National Medical Products Administration of China and 249 first-time registration certificates in 43 overseas markets [2] - The focus remains on enhancing financial health, concentrating on core businesses, and promoting high-quality and stable business development [2]